These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30019101)

  • 41. Lower Serum Sodium Levels Are Associated with the Therapeutic Effect of Sorafenib on Hepatocellular Carcinoma.
    Kegasawa T; Sakamori R; Maesaka K; Yamada R; Tahata Y; Urabe A; Kodama T; Hikita H; Imanaka K; Ohkawa K; Hiramatsu N; Oshita M; Yamada Y; Inada M; Yakushijin T; Imai Y; Tatsumi T; Takehara T
    Dig Dis Sci; 2021 May; 66(5):1720-1729. PubMed ID: 32556820
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].
    Turnes J; Díaz R; Hernandez-Guerra M; Gómez M; Castells L; Bustamante J; Espinosa MD; Fernández-Castroagudín J; Serrano T; Rendón P; Andrade R; Salgado M; Arenas J; Vergara M; Sala M; Polo BA; Granizo IM; Gonzálvez ML; Viudez A
    Gastroenterol Hepatol; 2015 Apr; 38(4):263-73. PubMed ID: 25583146
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use.
    Kuo YH; Wang JH; Hung CH; Rau KM; Wu IP; Chen CH; Kee KM; Hu TH; Lu SN
    J Gastroenterol Hepatol; 2017 Dec; 32(12):1975-1981. PubMed ID: 28295594
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib.
    Howell J; Pinato DJ; Ramaswami R; Arizumi T; Ferrari C; Gibbin A; Burlone ME; Guaschino G; Toniutto P; Black J; Sellers L; Kudo M; Pirisi M; Sharma R
    Oncotarget; 2017 May; 8(22):36161-36170. PubMed ID: 28212535
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma.
    Jouve JL; Lecomte T; Bouché O; Barbier E; Khemissa Akouz F; Riachi G; Nguyen Khac E; Ollivier-Hourmand I; Debette-Gratien M; Faroux R; Villing AL; Vergniol J; Ramee JF; Bronowicki JP; Seitz JF; Legoux JL; Denis J; Manfredi S; Phelip JM;
    J Hepatol; 2019 Sep; 71(3):516-522. PubMed ID: 31125576
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study.
    Noda S; Hira D; Osaki R; Fujimoto T; Iida H; Tanaka-Mizuno S; Andoh A; Tani M; Ikeda Y; Morita SY; Terada T
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):129-139. PubMed ID: 32588123
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Effect of ozone oil for prevention and treatment of sorafenib-induced hand-foot skin reactions: a randomized controlled trial].
    Chen X; Jiang Y; Zhang Y; Dai W; Fan R; Weng X; He P; Yan F; Guo Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2020 Oct; 40(10):1488-1492. PubMed ID: 33118519
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness and the strategy to treat the side effects of sorafenib administration after transarterial chemoembolization in advanced hepatocellular carcinoma patients.
    Zhang K; Sun X; Xie F; Jian W; Li C
    J Cancer Res Ther; 2018 Jan; 14(1):196-200. PubMed ID: 29516985
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of early adverse events resulting in sorafenib dose adjustments on survival outcomes of advanced hepatocellular carcinoma patients.
    Ruanglertboon W; Sorich MJ; Rowland A; Hopkins AM
    Int J Clin Oncol; 2020 Sep; 25(9):1672-1677. PubMed ID: 32417993
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors.
    Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Saito T; Motoyama T; Suzuki E; Tawada A; Kanai F; Yokosuka O
    Invest New Drugs; 2015 Jun; 33(3):729-39. PubMed ID: 25861764
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival.
    Abdel-Rahman O; Lamarca A
    Expert Rev Gastroenterol Hepatol; 2017 Jan; 11(1):75-83. PubMed ID: 27882800
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of the Prognostic Nutritional Index on the Survival of Japanese Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Retrospective Study.
    Hatanaka T; Kakizaki S; Uehara D; Nagashima T; Ueno T; Namikawa M; Saito S; Hosonuma K; Suzuki H; Naganuma A; Takagi H; Sato K; Uraoka T
    Intern Med; 2019 Jul; 58(13):1835-1844. PubMed ID: 30918170
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lactate dehydrogenase is a prognostic indicator in patients with hepatocellular carcinoma treated by sorafenib: results from the real life practice in HBV endemic area.
    Li MX; Zhao H; Bi XY; Li ZY; Yao XS; Li H; Huang Z; Han Y; Zhou JG; Zhao JJ; Zhang YF; Zhao DB; Cai JQ
    Oncotarget; 2016 Dec; 7(52):86630-86647. PubMed ID: 27880930
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tolerance and outcomes of sorafenib in elderly patients treated for advanced hepatocellular carcinoma.
    Williet N; Clavel L; Bourmaud A; Verot C; Bouarioua N; Roblin X; Merle P; Phelip JM
    Dig Liver Dis; 2017 Sep; 49(9):1043-1049. PubMed ID: 28712860
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea.
    Lee MJ; Chang SW; Kim JH; Lee YS; Cho SB; Seo YS; Yim HJ; Hwang SY; Lee HW; Chang Y; Jang JY
    Invest New Drugs; 2021 Feb; 39(1):260-268. PubMed ID: 32749658
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib.
    Labeur TA; Berhane S; Edeline J; Blanc JF; Bettinger D; Meyer T; Van Vugt JLA; Ten Cate DWG; De Man RA; Eskens FALM; Cucchetti A; Bonnett LJ; Van Delden OM; Klümpen HJ; Takkenberg RB; Johnson PJ
    Liver Int; 2020 Jan; 40(1):215-228. PubMed ID: 31579990
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma.
    Zhou L; Li J; Ai DL; Fu JL; Peng XM; Zhang LZ; Wang JY; Zhao Y; Yang B; Yu Q; Liu CZ; Wang HM
    Jpn J Clin Oncol; 2014 Aug; 44(8):711-7. PubMed ID: 24855686
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
    Johnson PJ; Qin S; Park JW; Poon RT; Raoul JL; Philip PA; Hsu CH; Hu TH; Heo J; Xu J; Lu L; Chao Y; Boucher E; Han KH; Paik SW; Robles-Aviña J; Kudo M; Yan L; Sobhonslidsuk A; Komov D; Decaens T; Tak WY; Jeng LB; Liu D; Ezzeddine R; Walters I; Cheng AL
    J Clin Oncol; 2013 Oct; 31(28):3517-24. PubMed ID: 23980084
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hand-foot syndrome due to sorafenib in hepatocellular carcinoma treated with vitamin E without dose modification; a preliminary clinical study.
    Bozkurt Duman B; Kara B; Oguz Kara I; Demiryurek H; Aksungur E
    J BUON; 2011; 16(4):759-64. PubMed ID: 22331734
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial.
    Kondo M; Morimoto M; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Aikata H; Hatanaka T; Takizawa D; Matsunaga K; Okuse C; Suzuki M; Taguri M; Ishibashi T; Numata K; Maeda S; Tanaka K
    BMC Cancer; 2019 Oct; 19(1):954. PubMed ID: 31615466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.